Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.
Santiago-Setien P, Barquín-Rego C, Hernández-Martínez P, Ezquerra-Marigomez M, Torres-Barquin M, Menéndez-Garcia C, Uriarte F, Jiménez-López Y, Misiego M, Sánchez de la Torre JR, Setien S, Delgado-Alvarado M, Riancho J.
Santiago-Setien P, et al. Among authors: riancho j.
Front Immunol. 2023 Feb 1;14:1086028. doi: 10.3389/fimmu.2023.1086028. eCollection 2023.
Front Immunol. 2023.
PMID: 36817456
Free PMC article.